Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination

Res Pract Thromb Haemost. 2022 Jun 21;6(4):e12750. doi: 10.1002/rth2.12750. eCollection 2022 May.

Abstract

Background: Severe side effects after vaccination with coronavirus disease 2019 (COVID-19) vaccines are rare but can be fatal. To date, vaccine-induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID-19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine.

Key clinical question: The Key Clinical Question was to determine whether inactivated COVID-19 vaccines could induce VITT and how to diagnose and treat such cases.

Clinical approach and conclusions: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti-heparin-platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high-dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.

Keywords: COVID‐19; SARS‐CoV‐2; Sinopharm; VITT; thrombosis; vaccine.

Publication types

  • Case Reports